SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : ARIAD Pharmaceuticals
ARIA 23.990.0%Feb 17 4:00 PM EST
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: jesspro who wrote (4350)8/3/2016 9:36:27 PM
From: jaybe  Read Replies (1) of 4474
 
ALTA-1L allows one line of prior chemo, ALEX (alectinib) trial was treatment-naive. Both are definitely TKI-naive.

I suspect very modest off-label 1L use after first data cut at ASCO 2018, by which time alectinib will be SOC in 1L in both US & EU. It will take ALTA-1L another year for data to show greater benefit of mPFS over alectinib's projected ~18-20 months (J-ALEX trial was over 22 months), at which point 1L approval for briga will be imminent.
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News